IQN Path Selects SeraCare Life Sciences for First-Ever Tumor Mutational Burden External Quality Assessment Program

International expert group focused on improving quality of clinical biomarker testing launching pilot TMB proficiency program in Spring 2019     MILFORD, Mass., WED. March 27, 2019 /PRNewswire/ — SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today their successful selection as a technology partner read more…